Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and a leading cause of preventable vision loss worldwide. It arises from chronic hyperglycemia–driven damage to retinal endothelial cells, pericytes, and neuroglial elements. Over time, DR progresses along a spectrum from early microvascular lesions to proliferative disease characterized by retinal neovascularization, macular edema, and increased risk of vitreous hemorrhage. While classical risk reduction focuses on glycemic control, blood pressure, and lipid management, accumulating evidence indicates that systemic inflammation, oxidative stress, and dysregulated metabolic signaling—often shaped by the gut microbiome—contribute to retinal injury.
The gut–retina axis has become a biologically plausible framework linking intestinal dysfunction to ocular microvascular pathology. Dysbiosis (altered microbial composition and function) can change the production of microbial metabolites, disrupt intestinal barrier integrity, and promote translocation of pro-inflammatory molecules into circulation. These events increase systemic immune activation and endothelial stress, thereby accelerating mechanisms central to DR.
A key metabolite highlighted in emerging research is indole-3-propionic acid (IPA), a tryptophan-derived compound produced by gut microbes. IPA has been associated with anti-inflammatory and barrier-supporting effects in preclinical models. Mechanistically, IPA may modulate host immune responses by influencing signaling pathways related to oxidative stress and cytokine production. It can also affect the function of epithelial tight junctions and reduce the burden of gut-derived inflammatory signals reaching peripheral tissues. In the context of DR, such actions may translate into reduced retinal inflammation, improved endothelial survival, and attenuation of pathways leading to capillary dropout and neovascular stimulation.
DR pathobiology involves multiple, interlocking processes: (1) non-enzymatic glycation and advanced glycation end products that trigger receptor-mediated inflammatory cascades; (2) oxidative stress that damages cellular membranes and mitochondrial function; (3) activation of vascular permeability programs resulting in breakdown of the blood–retina barrier; and (4) hypoxia-driven angiogenic signaling, especially via VEGF-mediated pathways. Dysbiosis can intensify these mechanisms by increasing circulating inflammatory mediators and by shifting the metabolic milieu toward pro-oxidant and pro-immune states.
Importantly, IPA is not merely hypothesized to be protective; it is also being studied as a biomarker reflecting the gut’s metabolic state. A biomarker useful for DR should correlate with disease presence, progression, or therapeutic response. If IPA levels or functional signaling pathways reliably track with DR severity, clinicians could potentially use it to stratify risk, identify patients more likely to develop microvascular complications despite standard care, or monitor response to gut-targeted interventions.
A “novel therapeutic approach” built on IPA and gut dysbiosis generally entails correcting the underlying intestinal environment. Potential strategies under investigation may include dietary interventions that alter tryptophan metabolism, targeted microbial supplementation (probiotics or engineered consortia), or direct modulation of microbial metabolite production. Alternatively, therapeutic approaches might aim at restoring microbial metabolic pathways that favor beneficial metabolites such as IPA. Although clinical translation requires rigorous validation, the concept represents a shift from retina-centric treatment alone toward a systemic, multi-organ strategy.
For clinicians and patients, this line of research emphasizes that DR is not solely an ocular disease but a systemic complication influenced by metabolic and inflammatory networks. Nevertheless, standard-of-care remains essential: optimizing glycemic control, managing comorbid cardiovascular risk factors, and using ophthalmic interventions such as anti-VEGF injections, retinal photocoagulation, and appropriate management of diabetic macular edema. Gut-based strategies should be considered investigational and adjunctive until validated in human trials.
Future studies should address causal inference and clinical utility. Key questions include whether changes in IPA precede DR onset (causality), whether IPA predicts progression independent of traditional markers (risk stratification), and whether interventions that raise or mimic IPA produce measurable retinal benefits (therapeutic effectiveness). Integrating metabolomics with retinal imaging outcomes (e.g., optical coherence tomography for edema and fluorescein angiography for vascular leakage) can clarify the temporal relationship between gut metabolites and retinal pathology.
In summary, diabetic retinopathy reflects complex microvascular dysfunction driven by hyperglycemia, inflammation, and oxidative stress. Research connecting indole-3-propionic acid to gut dysfunction offers a compelling model of the gut–retina axis, with IPA potentially serving as both a biomarker and a target for novel therapeutic strategies. Source: Gut_BMJ (Creator) — #GUTVideo post discussing Prasad et al. paper on indole-3-propionic acid and diabetic retinopathy.
Gut Journal: Watch the latest #GUTVideo on the paper by Prasad et al. “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” which investigates how disruptions in gut health contribute to diabetic retinopathy (DR), a major. #breaking
— @Gut_BMJ May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
